Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing Interview with:
Hiroyuki Mochizuki, M.D., Ph.D
Professor & Chairman
Department of Pediatrics
Tokai University School of Medicine
Japan What is the background for this study? What are the main findings?

Response: My major is allergy and respiratory health of children. By this examination, we wanted to know the true influence of respiratory syncytial virus infection on childhood atopic asthma. We have confirmed that infantile asthma is heterogenic, and at least two kinds of phenotypes are present. What should readers take away from your report?

Response: If two kinds of phenotypes are present, we need two or more kinds of therapy techniques against infantile asthma. An early definitive diagnosis will be necessary. What recommendations do you have for future research as a result of this study?

Response: Diagnostic criteria in infantile asthma and examination techniques should be considered. Is there anything else you would like to add?

Response: In our examination, the ratio of respiratory syncytial virus infection-induced recurrent wheezers and atopic recurrent wheezers/asthma was 50:50. Physicians think that most of asthmatic children are atopic. So, we need a new special idea of recurrent wheezing/asthma in an infantile period. Thank you for your contribution to the community.


Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing.
Hiroyuki Mochizuki ; Satoshi Kusuda ; Kenji Okada ; Shigemi Yoshihara ; Hiroyuki Furuya ; Eric A. F. Simões
Accepted: February 03, 2017
Published Online: February 02, 2017
American Journal of Respiratory and Critical Care Medicine

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on

[wysija_form id=”5″]

Last Updated on February 8, 2017 by Marie Benz MD FAAD